Evaluation of the Efficacy of Dissociation-Focused Cognitive Behavior Therapy

NCT06917209 · tracked via the Priya Life Science France tracker

Sponsor

University Hospital, Tours

Phase

Not applicable

Started

2025-05-16

Last updated

2026-07-09

Condition(s) studied

Dissociative Disorder

Investigational drug(s) / intervention(s)

CBT-CD psychotherapy

CBT-CD psychotherapy: 9 weekly sessions of CBT-CD psychotherapy

Study summary

Dissociative symptoms and disorders are particularly prevalent in the general population and among people suffering from psychiatric disorders. To date, no treatment has proven effective for this type of problem. Exploratory studies (without control group) have been carried out. Among these studies, dissociation-focused cognitive behavioral therapy (DF-CBT) seems promising. DF-CBT is based on a solid empirical model that has received numerous scientific evidence.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * ≥ 18 years * Membership of a social security scheme * Participant's express consent * Have at least one diagnosis of dissociative disorder among the following: depersonalization/derealization disorder, dissociative identity disorder, unspecified dissociative disorder. * Be able to carry out psychotherapy sessions. * If taking psychiatric medication, treatment must have been stable for at least 30 days. Exclusion Criteria: * Present one of the following current diagnoses: substance use disorder (excluding tobacco), neurodevelopmental disorder, anorexia nervosa, severe depressive disorder, schizophrenia spectrum disorder, bipolar disorder, personality disorder other than borderline personality disorder. * Present cognitive deficits. * Be engaged in psychotherapeutic work. * Be undergoing benzodiazepine treatment. * Pregnant women and breastfeeding women

Primary outcome measure(s)

Difference in Dissociative Experience Scale (DES) — Between randomization and 3 months after
Difference in Dissociative Experience Scale (DES) between randomization and 3 months after. The DES assesses dissociation through 28 items. The total score ranges between 0 and 100, where high scores indicate high levels of dissociation.

Trial sites (8)

Facility	City	Region	Status
Psychiatrie / CHU ANGERS	Angers	France	Not Yet Recruiting
Centre régional du Psychotraumatisme des Hauts de France / CHU LILLE	Lille	France	Not Yet Recruiting
Urgences psychiatrique / CHU MONTPELLIER	Montpellier	France	Not Yet Recruiting
Unité de neuromodulation en psychiatrie / CHU NANTES	Nantes	France	Not Yet Recruiting
Centre départemental de Psychotraumatologie (unité TCC) / ORLEANS	Orléans	France	Not Yet Recruiting
Centre Régional du Psychotraumatisme du Grand Est / CHU STRASBOURG	Strasbourg	France	Not Yet Recruiting
Centre Régional du Psychotraumatisme CRP / CHRU TOURS	Tours	France	Recruiting
Unité de Neuromodulation / CHU de Tours	Tours	France	Recruiting

More University Hospital, Tours trials in France

Impact of a Coordinated Dietetic-adapted Physical Activity Program on the Percentage of Lean Body Mass in Adults With Cystic Fibrosis Treated With Elexacaftor-Tezacaftor-Ivacaftor: Multicentre Randomised Controlled Trial Recruiting

Morphine Clearance and Glomerular Filtration in Sickle Cell Patients in Crisis in Intensive Care Recruiting

Individual Neurophysiological Sensory Profiles in People With and Without Neurodevelopmental Disorders Recruiting

Apneic Oxygenation With High-flow Nasal Oxygenation After Preoxygenation With Noninvasive Ventilation Before Intubation in Hypoxemic Patients in Intensive Care Unit. Starting soon

Awake Prone Positioning of Patients Suffering Community Acquired Pneumonia Requiring Nasal High Flow Therapy Recruiting

Other trials for the same condition

Prevalence of Dissociative Identity Disorder in At-risk Outpatient Groups Reporting Childhood Trauma. Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06917209 on ClinicalTrials.gov ↗ ← All trials in France